COVID-19 (RECOVERY) で入院した患者におけるアジトロマイシン:ランダム化,制御,オープンラベル,プラットフォーム試験
Lancet (London, England)
|February 5, 2021
まとめ
RECOVERY試験では,アジトロマイシンは入院したCOVID-19患者の生存率を向上させなかった. その使用は,COVID-19の治療ではなく,明確な抗菌薬の指示のある症例に限定されるべきです.
科学分野:
- 臨床医学
- 感染症
- 薬理学について
背景:
- 免疫調節性を持つ抗生物質であるアジトロマイシンは,COVID-19の治療のために研究されました.
- この研究では,入院したCOVID-19患者のアジトロマイシンの安全性と有効性を評価した.
研究 の 目的:
- 住院中のCOVID-19患者の臨床結果を改善するアジトロマイシンの有効性を評価する.
- この患者群でアジトロマイシンが28日間の死亡率を減少させるかどうかを判断する.
主な方法:
- ランダム化され,制御され,オープンラベル,適応性プラットフォーム試験 (RECOVERY) で,7,763人の入院COVID-19患者が参加した.
- 患者は通常治療とアジトロマイシン (毎日500 mg) または通常治療のみを受けた.
- 主なアウトカムは28日間の全原因死亡率でした.
主要な成果:
- アジトロマイシン投与は28日間の全因死亡率を有意に変化させなかった (22%両群;率比0. 97,95%CI0. 87-1. 07).
- 病院滞在期間や28日生存率は有意な差異は認められなかった.
- 機械的換気または死亡の複合エンドポイントも,グループ間で有意な違いを示さなかった.
結論:
- アジトロマイシンは,入院したCOVID-19患者の生存率または他の臨床結果の改善に効果的ではありません.
- 住院中のCOVID-19患者のアジトロマイシンの使用は,細菌感染が確認された場合に限られるべきである.
さらに関連する動画
関連する概念動画
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
735
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
735
01:28Pneumonia IV: Management
580
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
580
01:18Endocarditis III: Medical Management
95
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
95
01:28Antimicrobial Effectiveness
765
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
765
01:26Tonsillitis II: Management
260
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
260
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
135
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
135